SEARCH

SEARCH BY CITATION

References

  • 1
    Rotella CM, Pala L, Mannucci E. Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 2005; 28: 746758.
  • 2
    Pala L, Mannucci E, Pezzatini A et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003; 310: 2831.
  • 3
    Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 11681172.
  • 4
    Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007; 100: 824829.
  • 5
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 16961705.
  • 6
    Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 16541661.
  • 7
    Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycaemic control of type 2 diabetes. Regul Pept 2004; 117: 7788.
  • 8
    Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492498.
  • 9
    Exenatide. Summary of product characteristics. 2007. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/byetta/H-698-PI-en.pdf (accessed 01 November 2007)
  • 10
    Cvetković RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67: 935954.
  • 11
    Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev 2008; 4: 101109.
  • 12
    Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173181.
  • 13
    Kolterman OG, Buse JB, Fineman MS et al. Synthetic Exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 30823089.
  • 14
    Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycaemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulphonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 23702377.
  • 15
    Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 59915997.
  • 16
    Linneberg H, Park S, Kothare P et al. Exenatide delays gastric emptying and reduces postprandial glucose in type 2 diabetes. Diabetologia 2006; 49 (Suppl. 1): 140, Abstract 0223.
  • 17
    Calara F, Taylor K, Han J et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005; 27: 210215.
  • 18
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in sulphonylurea -treated patients with type 2 diabetes. Diabetes Care 2004; 27: 26282635.
  • 19
    Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycaemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulphonylurea. Diabetes Care 2005; 28: 10831091.
  • 20
    DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycaemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 10921100.
  • 21
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 2005; 143: 559569.
  • 22
    Nauck MA, Duran S, Kim D, Johns D, Festa A, Trautman M. Effects of exenatide compared with twice-daily biphasic insulin aspart in patients with type 2 diabetes using metformin and a sulphonylurea. Diabetologia 2006; 49 (Suppl. 1): 3, Abstract 0001.
  • 23
    Barnett AH, Trautmann M, Burger J et al. A comparison of exenatide and insulin glargine in patients using a single oral antidiabetic agent. Diabetologia 2006; 49 (Suppl. 1): 474, Abstract 0782.
  • 24
    Yurgin N, Secnik K, Hayes C, Johns D, Trautmann M. Patients reported outcomes in patients with type 2 diabetes treated with exenatide compared to biphasic insulin aspart. Diabetologia 2006; 49 (Suppl. 1): 474475, Abstract 0783.
  • 25
    Zinman B, Hoogwerf BJ, Durán García S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477485.
  • 26
    Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275286.
  • 27
    Buse JB, Klonoff DC, Nielsen LL et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139153.
  • 28
    Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436447.
  • 29
    Heine RJ, Van Gaal LF, Johns D et al. Exenatide achieved equivalent glycaemic control to insulin glargine with weight reduction, independently from baseline BMI, in metformin and sulphonylurea -treated type 2 diabetes. JEI 2007; 30 (Suppl. 4): 105.
  • 30
    Kendall D, Bhole D, Guan X et al. Exenatide treatment for 82 weeks reduced C-reactive protein HbA1c and body weight in patients with type 2 diabetes mellitus. Diabetologia 2006; 49 (Suppl. 1): 475, Abstract 0784.
  • 31
    Kapitza C, Nauck MA, Kim D, Trautmann M, Johns D, Festa A. Long-term treatment with exenatide improved postprandial glycaemic control and was associated with a shift from small to large HDL snf LDL particles. Diabetologia 2006; 49 (Suppl. 1): 140141, Abstract 0224.
  • 32
    Kendall D, Blonde L, Mac S et al. Improvements in cardiovascular risk factors accompanied improved glycaemic control and weight reduction in patients with type 2 diabetes treated with exenatide for 3.5y. Diabetes 2007; 56 (Suppl. 1): A149.
  • 33
    Heine RJ, Van Gaal LF, Johns D et al. Exenatide achieved equivalent glycaemic control to insulin glargine in metformin and sulphonylurea -treated type 2 diabetics: blood pressure results. JEI 2006; 29 (Suppl. 4): OC28.
  • 34
    Secnik Boye K, Matza LS, Oglesby A et al. Patients-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006; 4: 8087.
  • 35
    Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 2004; 20: 411417.
  • 36
    Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006; 29: 471.
  • 37
    Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 148793.
  • 38
    Cavalot F, Petrelli A, Traversa M et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006; 91: 813819.
  • 39
    De Vegt F, Dekker JM, Ruhe HG et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926931.
  • 40
    Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20: 163169.
  • 41
    Rodriguez BL, Lau N, Burchfiel CM et al. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. Diabetes Care 1999; 22: 12621265.
  • 42
    Home P, Mant J, Diaz J, Turner C, Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008; 336: 13061308.
  • 43
    American Association of Clinical Endocrinologist. Road map to achieve glycemic goals. Available from URL: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf (accessed 01 November 2007)
  • 44
    International Diabetes Federation. Guidelines on the postprandial glucose control. http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf (accessed 01 November 2007)